Company intelligence / Profile preview

Nanostim

Sunnyvale, California, United Statescardiovascular.abbott ↗

Ownership: Private
Development stage: Commercial

Overview

Nanostim developed the world’s first leadless cardiac pacemaker, which was successfully implanted in patients as part of the LEADLESS Study. The device received CE Mark approval and was conditionally approved by the FDA for pivotal clinical trials in the U.S. prior to acquisition by St. Jude Medical.

Therapeutic areas: Cardiovascular
Modalities: DeviceImplantable medical device
Industry: Implantable Medical Devices

Partnerships

St. Jude Medical (investment and exclusive option prior to acquisition)

Beyond the preview

Go deeper on Nanostim.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanostim.

Explore the full profile